iuvando Health

Great pleasure to participate in the #ZEITfürForschung event hosted by ZEIT Verlagsgruppe and Bayer, where we explored critical topics shaping the future of innovation ecosystems in Germany and across Europe. It was truly inspiring to engage with Stefan Oelrich and Hildegard Bentele on how we can unlock the immense potential of Germany's and Europe's research landscapes. We also discussed the promising opportunities presented by the Medicines Research Act (Medizinforschungsgesetz), which aims to strengthen Germany as a hub for cutting-edge research. Central to our conversation was the importance of enabling early patient access to innovative treatments through clinical trials. This act not only paves the way for better healthcare outcomes but also creates opportunities to advancing medical innovation.   At iuvando Health, we are deeply committed to leveraging a digital and human-centric approach to bring innovative cancer therapies to patients. By fostering collaboration, exploring new methods of evidence generation, and nurturing a strong innovation ecosystem, we can ensure that Europe remains at the forefront of global medical advancements. A special thank you to Katja Schubert and Katja Leppler for the excellent event planning and to Jan Schweitzer, Dr. Mark Schiffhauer and the ZEIT Verlagsgruppe for facilitating such an insightful discussion and the opportunity to share our vision for the future of healthcare. Photos: © Kevin Fuchs #ZEITfürForschung #InnovationInHealthcare #CancerResearch #DigitalHealth #ClinicalTrials #MedicalResearchAct #OncologyCare

We need your support! 🎉   We're honored and thrilled to be among the Top 10 German healthcare startups nominated for the Health-i Award 2024 by Die Techniker and Handelsblatt. Our team at iuvando Health is advancing the fight against cancer and helping patients to find and access clinical trials. Now it's your turn: please vote for us and help us reach the Top 3! 🏆 Your vote counts and will directly influence the jury's decision.   📅 You can vote here (until August 29, 2024): https://lnkd.in/dK6XutyY   Thank you for your support! 🙏   #healthi #healthcare #digitalization #innovation #startups   Congratulations to our fellow nominees who we are excited to compete with: DiaMonTech AG, EASEE®Epilepsie, fabel, hellomed.com, LillianCare, Pathmate Technologies AG, MySympto, Recovery Cat, and SmartAIs Andreas von Münchow, Dr. Jens Baas, Ariel Dora Stern, Charlotte Haunhorst, Susan Koll, Frauke Pallentin, Yvonne Aragon, Friederike Rosemann, and Katharina Ungar

Truly enjoyed speaking with Inga Bergen on the Visionäre der Gesundheit (m/w/d) podcast about the importance of patient access to clinical trials in oncology. For me personally and our team at iuvando Health, the integration of technology, digitalization, and empathy centered around real patient needs (and not the other way around) remain a critical priority towards a solution! Thank you very much for the engaging and wide-ranging conversation and for having me, Inga! Link to episode: https://lnkd.in/gga6bHcm

I am immensely grateful to share my podcast debut on "Krebs! Was nun?" with Nils F. Glaubke! Host Nils was diagnosed with stage IV lung cancer at the age of 39. Faced with this daunting diagnosis, Nils has turned his personal fate into a mission to empower and educate other cancer patients. This episode delves into the crucial role of clinical trials in cancer research and treatment. We addressed a common concern: the fear that participants in clinical trials are merely "guinea pigs." This perception is not only far from reality, it’s post-factual and undermines the trust in science and evidence-based medicine. It needs to be corrected. Clinical trials in oncology are designed with highest ethical standards and are vital for developing new and effective cancer therapies. They offer access to cutting-edge treatments that might not yet be available to the general public. For many patients, clinical trials provide a lifeline, potentially extending their lives or improving their quality of life. The rigorous process of informed consent ensures that patients are thoroughly educated about the trial's purpose, procedures, risks, and benefits before deciding to participate. This empowers patients to be active decision-makers. Our conversation also touched on the broader impact of clinical trials on the medical community and future patients. Each trial contributes valuable data that improves our understanding of cancer and refines existing treatments. The advancements made through these trials can lead to breakthroughs that benefit countless individuals worldwide. Speaking with Nils who benefited from our work at iuvando Health was profoundly inspiring. It was the pressing needs of patients like Nils that motivated us to start the company in 2019. Witnessing the impact of our efforts come full circle - helping patients find new treatment options and then having those patients educate and guide others - is truly gratifying. I would like to invite you all to listen to our conversation and follow Nils' podcast. Let's continue to build a future where every patient's voice is heard, and every fate is met with compassion and cutting-edge solutions. Thank you, Nils for this wonderful opportunity to speak with you and all your remarkable work for patients!

I am deeply honored and humbled to be awarded the German Startup Award as Impact Entrepreneur of the Year 2024. This recognition is certainly not just mine, but belongs to all those who believed in our vision and are working tirelessly to make it a reality. A special thanks to my friend and co-founder Dr. Benjamin Hanfstein and the entire team at iuvando Health, our partners across patient organizations, cancer centers, health insurances, and the pharmaceutical industry - and last but not least - my friends and family! “I am very optimistic that the lights will not go out soon in Germany, but that we have not even switched them on yet in most areas,” said Verena Pausder, Chairwomen of the German Startup-Verband in her inspiring opening remarks at the award ceremony of the German Startup Awards 2024 this week in Berlin.   To extend Verena’s metaphor: for me, the beauty and fascination of entrepreneurship lie in exactly that opportunity - the attempt to enter areas of darkness, install light switches, and turn them on. As a physician and scientist in the field of cancer medicine, founding a company was not something I had planned or even was prepared for. All the more grateful I am for all the lows and highs I encountered along the path of entrepreneurship – they have been instrumental for my professional and personal growth.   I would like to especially thank the Startup-Verband for their important work and a fantastic evening, Germany’s Vice Chancellor Robert Habeck for his empowering words and support of the startup ecosystem, Dr. Maximilian Oehl and Janna Linke for their very warm welcome on stage, and the jury for selecting us.    Let's all together think about how to make dreams possible, creatively approach solutions, and most importantly, start acting – let’s switch the lights on!   Congratulations to my fellow nominees Ben Unterkofler and Philipp Schröder as well as to the other awardees Kristina Nikolaus, Jonas Andrulis, Nils Aldag, Angela Relógio, Ish Dhand, Kristina Lunz, Gloria Baeuerlein, and Jan Miczaika!

I am immensely excited to be joining the EUROPE 2024 conference in Berlin starting today jointly hosted by DIE ZEIT, Handelsblatt, Verlag Der Tagesspiegel, and WirtschaftsWoche. The conference will be discussing Europe's competitiveness and its political and economic future with German Chancellor Olaf Scholz, Estonian Prime Minister Kaja Kallas, German Federal Minister for Economic Affairs and Climate Action Robert Habeck, his French counterpart Bruno Le Maire and many other distinguished guests. I'm very much looking forward to our panel "Research & Progress - Are the Conditions in Place?" with Andreas Gerber and Gabriele Katzmarek, moderated by Jürgen Klöckner as part of the "Health and Innovation" focus topic. Being a physician and entrepreneur, these trying times are about turning challenges into opportunities. I’m convinced that the field of healthcare/medicine needs to be a trailblazer to showcase how scientific discoveries are translated into practical solutions that have a tangible social, economic and political impact. Further information: https://lnkd.in/eHAk9-2e #Europe2024 #Europe20xx #HealthInnovation

As 2023 comes to a close, I'm filled with immense gratitude for the incredible journey we've navigated at iuvando Health. This year has underscored our unwavering commitment to making a tangible impact on the lives of numerous cancer patients, facilitating access to cutting-edge therapies in clinical trials across Europe. I would like to reflect on some of the key topics that have defined 2023 for us: 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻, 𝘁𝗵𝗲 𝗰𝗼𝗿𝗻𝗲𝗿𝘀𝘁𝗼𝗻𝗲 𝗼𝗳 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 - walls of silos crumbled as we forged bridges with patient advocacy groups, leading cancer centers, healthcare insurers, and global pharmaceutical companies. Collaboration, not competition, fueled our year. Ensuring equitable access to life-saving therapies in clinical trials requires collective efforts across diverse stakeholders. 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗺𝗲𝗲𝘁𝘀 𝗵𝘂𝗺𝗮𝗻 𝗰𝗼𝗺𝗽𝗮𝘀𝘀𝗶𝗼𝗻 - what sets iuvando Health apart is our fusion of technology and human compassion. Our service transcends algorithms, focusing on understanding the unique treatment situation of each patient. In a world where empathy is as crucial as technological innovation, we stand as a company deeply committed to the well-being of those we serve. 𝗧𝗿𝗮𝗻𝘀𝗮𝘁𝗹𝗮𝗻𝘁𝗶𝗰 𝗮𝗱𝘃𝗼𝗰𝗮𝗰𝘆 - bold steps were taken in 2023 to advocate for impactful change, engaging high-level politicians, government administrators, and business leaders. The goal: fostering transatlantic partnership, breaking down barriers, and ensuring our impact extends across borders. 𝗧𝗲𝗮𝗺 - to my iuvando Health team, thank you! Your dedication and collaborative spirit have been the cornerstone of our success. Teamwork truly makes the dream work, and I'm proud to work with such exceptional colleagues. 𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗼 𝘁𝗵𝗲 𝗨𝗦 𝗶𝗻 𝟮𝟬𝟮𝟰 - exciting news awaits! In 2024, iuvando Health is expanding to the United States. This marks not only a geographic milestone but a broader commitment to reaching more patients, forging new partnerships, and making a difference in the global fight against cancer. As we step into 2024, we carry a renewed purpose and a vision for a future where clinical trials are not a last resort but a beacon of hope for every cancer patient. Our commitment remains strong: simplifying access to trials, advocating for patient-centric research, and empowering individuals to take an active role in healthcare decisions. Here's to another year of impactful collaboration, compassionate innovation, and advancing the global fight against cancer. Onward to 2024!